Physician profile
Katlyn D Dailey
NPI 1780124925
$3,005.97
in general payments reported to CMS, 2019-2025
16 companies · $243 in 2025
The $243 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $211 · 2022: $674 · 2023: $966 · 2024: $911 · 2025: $243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,120.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,087.51 | 2021-2024 | |
| Alkermes, INC. | $348.55 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| Supernus Pharmaceuticals, INC. | $250.30 | 2023-2025 | Qelbree, Qelbree, Oxtellar Xr |
| Teva Pharmaceuticals USA, INC. | $227.57 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $208.00 | 2022-2024 | Rexulti, Abilify Maintena |
| Lundbeck LLC | $192.07 | 2022-2024 | Rexulti, Brintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $147.99 | 2022-2024 | Caplyta |
| Sunovion Pharmaceuticals INC. | $137.43 | 2021-2022 | |
| Indivior INC. | $107.12 | 2022-2024 | Perseris |
| Janssen Pharmaceuticals, INC | $95.39 | 2023-2024 | Invega, Spravato |
| Axsome Therapeutics, INC. | $51.77 | 2023-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $48.42 | 2023-2024 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $46.20 | 2024-2025 | Cobenfy |
| Noven Therapeutics, LLC | $28.31 | 2022-2023 | Xelstrym |
| Vanda Pharmaceuticals INC. | $16.25 | 2025 | Hetlioz, Fanapt |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $13.09 | 2023 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katlyn Dailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.